BEVERLY HILLS, Calif., July 25 /PRNewswire/ -- Hurel Corporation ("Hurel")
announced today it has entered into a contract with Johnson & Johnson
Pharmaceutical Research & Development, L.L.C., ("J&JPRD") under which J&JPRD
becomes the first pharmaceutical company to enter the Joint Scientific
Collaboration ("JSC") being organized by Hurel.
Under the agreement, J&JPRD will provide both scientific guidance and
funding as Hurel performs a one-year research and development program aimed at
validating its microfluidic, "in vivo-surrogate" cell-based assay platform
technology (please see below), and readying Hurel's first product for general,
Hurel is currently holding discussions with several additional Fortune 50
pharmaceutical and consumer products firms that have also expressed interest
to enter and participate in the Joint Scientific Collaboration. Hurel
projects its JSC laboratory activities to commence in the third quarter of
Mr. Robert M. Freedman, President and Chief Executive Officer of Hurel
Corporation, said, "Hurel's simple technology will enable researchers to
achieve experimental endpoints of dramatically improved concordance with, and
predictive relevancy to, the in vivo performance of drugs in humans. Hurel's
predictive accuracy will afford greatly improved selectivity in promoting
preclinical drug candidates into animal studies, and as such Hurel will become
an important new technological substitute for animal testing. I'd like to
thank and congratulate J&JPRD in being the first pharmaceutical research and
development organization to join, and thereby in enabling us to launch, the
Hurel Joint Scientific Collaboration."
Dr. Leslie Z. Benet, Professor of Pharmaceutical Sciences at UCSF and
Chairman of Hurel's Scientific Advisory Board, said, "At present there are no
simple, rapid preclinical tools to mimic the in vivo interplay of enzymes and
transporters. What is needed is a simple flow-through assembly that must be
amenable to incorporating hepatocytes and enterocytes from animal species but
also, alternatively, from humans, and should be high-throughput. Such a novel
preclinical tool would provide great insights into the ADME of new molecular
entities, and expose the reasons for the discordance often found between the
ADME characteristics of drug molecules across animal species versus humans. I
believe that Hurel is that novel preclinical tool. I am looking forward to
working with J&JPRD towards realizing Hurel's potential."
Hurel Corporation is the developer of patented, microfluidic "in
vivo-surrogate" assay platform technologies for cell-based studies.
Originally invented by Dr. Gregory Baxter (now Hurel's CSO) and Prof. Michael
Shuler at Cornell University, a Hurel(R) device comprises a "biochip" on which
reside a number of separate but microfluidically interconnected compartments.
The different compartments contain cultures of living cells drawn from and/or
representing different organs or tissues of a living animal. Microfluidic
channels between the compartments permit compounds and "blood surrogate" fluid
to recirculate as in a living system. The physical geometry of the system is
designed to simulate certain physiological parameters -- drug residence time,
circulatory transit time, fluid-to-tissue volume ratios, or others -- so as to
mimic relevant aspects of the physiology of the living animal.
The Company's initial product -- a microfluidic circuit that models
real-time protein binding, metabolism, and extraction in the liver -- will
comprise the world's first comprehensive, in vitro test of first-pass liver
bioavailability in humans or other species. Other Hurel applications slated
for early development include devices customized for studying various
multi-organ toxicities (e.g., liver/lung or liver/cardiac), as well as for
studying the integrated mechanisms of absorption and bioavailability of orally
Additional information is available at: www.hurelcorp.com.
Hurel is a registered trademark.
SOURCE Hurel Corporation